A Cholesterol Drug Has Been Available for a Decade. New Trial Data Suggests We've Been Under-Prescribing It to the Wrong Patients.

PCSK9 inhibitors have been FDA-approved since 2015. They lower LDL cholesterol by roughly 55%. The evidence for their cardiovascular benefit has been building for a decade. And yet only 3.3% of patients who are eligible for them actually receive a prescription — up from 0.5% when they launched, but still a fraction of the population that would benefit.

The latest data from the VESALIUS-CV trial, presented at the American College of Cardiology’s annual meeting this week, adds new weight to a question the cardiology community has been circling: are we treating the wrong patients?

What the trial found

VESALIUS-CV enrolled 12,257 patients at 774 sites across 33 countries — a large, well-powered trial with a median follow-up of 4.6 years. The defining characteristic of the study population: none of the patients had previously had a heart attack or stroke. This is primary prevention — treating people before they have their first event, not after.

Patients received evolocumab (Repatha) 140 mg every two weeks or matching placebo, added to standard statin therapy. LDL-C dropped from a median of 115 mg/dL to 45 mg/dL in the treatment group — compared to 111 mg/dL in the placebo group at 48 weeks.

The primary outcome results:

3-point MACE (coronary heart disease death, heart attack, or ischemic stroke): 336 events in the evolocumab group versus 443 in placebo — a 25% relative risk reduction.

4-point MACE (above plus ischemia-driven revascularization): 747 versus 907 — a 19% relative risk reduction.

The diabetes subgroup result presented at ACC 2026 this week: in high-risk diabetic patients who had never had a cardiovascular event, evolocumab reduced first MACE by 31%. This subgroup represents roughly one-third of the total study population.

Why this matters — and why it’s been ignored

The conventional approach to PCSK9 inhibitors has been secondary prevention: prescribe them to patients who have already had a heart attack or stroke to prevent the next one. VESALIUS-CV is the first major trial to demonstrate improved cardiovascular outcomes in patients who have never had an event.

The clinical implication, as the trial’s lead investigator Nicholas Marston put it: “I think this study changes the paradigm. It’s a message to physicians and patients that we don’t have to wait until someone has atherosclerosis to treat them intensively. We can — and should — be much more proactive.”

The shift being proposed: treat high-risk patients — particularly those with diabetes — to secondary prevention LDL targets (~45 mg/dL) before they have their first cardiovascular event, rather than waiting for the event to occur and then treating aggressively. The trial provides the evidence base for that approach.

The access problem that predates the new data

Even with the existing evidence — which has supported PCSK9 inhibitors for secondary prevention since 2017 — the drugs have been dramatically underused. The reasons are structural.

Insurance denials. Approximately 47% of patients prescribed PCSK9 inhibitors get coverage approved. Commercial insurers approve 24.4% of requests — less than one in four. Medicare approves 60.9%. The prior authorization process, which requires extensive documentation of statin failure before approval, functionally blocks most prescriptions before they are filled.

Cost. List price runs above $500 per month. Amgen introduced a direct-to-patient program (AmgenNow) in 2025 at approximately $239 per month — a significant reduction — but the list price remains the reference point for most insurance negotiations. Medicare Part D changes in 2026 are expected to improve access for seniors, but the commercial market remains constrained.

Prescriber inertia. Statins have been the standard cholesterol intervention for thirty years. PCSK9 inhibitors require an injection every two weeks. Shifting prescribing behavior at the population level is slow even when the evidence supports it.

What a standard-of-care shift would actually require

If cardiology guidelines update to incorporate VESALIUS-CV — which the ACC’s own trustee described as “practice-changing” — the downstream effects are significant.

Millions of high-risk diabetic patients without prior cardiovascular events would become guideline-eligible for PCSK9 inhibitor therapy. The current prescribing infrastructure — built around the assumption that only post-event patients are candidates — would need to expand substantially.

The insurer response is the critical bottleneck. Guidelines rarely translate immediately into coverage changes. The history of PCSK9 inhibitors since 2015 is a case study in that lag: robust evidence, narrow coverage, minimal penetration. Without parallel policy pressure on prior authorization and coverage criteria, new guidelines will produce new conversations in cardiologists’ offices that end with insurance denials.

The cost-effectiveness calculation shifts if the price continues falling. At $239 per month for a ten-year primary prevention course in a diabetic patient with elevated cardiovascular risk, the numbers are plausibly acceptable by health economics standards. At $500 per month, they are not.